Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | LTA4H | P09960 | 1/20 | 0.31 |
| ▸ | MME | P08473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17338688 | 1.00 | PDE4A (0.44) | PDE4ATSHRCYP2C9SMN1; SMN2ALDH1A1 | |
| SCHEMBL27294795 | 1.00 | PDE4A (0.44) | PDE4ATSHRCYP2C9SMN1; SMN2ALDH1A1 | |
| SCHEMBL6666971 | 1.00 | PDE4A (0.44) | PDE4ATSHRCYP2C9SMN1; SMN2ALDH1A1 | |
| SCHEMBL18120858 | 1.00 | PDE4A (0.44) | PDE4ATSHRCYP2C9SMN1; SMN2ALDH1A1 | |
| SCHEMBL15528782 | 1.00 | PDE4A (0.44) | PDE4ATSHRCYP2C9SMN1; SMN2ALDH1A1 | |
| Ethylene Glycol SCHEMBL28423287 | 0.91 | PDE4A (0.48) | PDE4ATSHRCYP2C9SMN1; SMN2ALDH1A1 | |
| SCHEMBL1846267 | 0.89 | SMN1; SMN2 (0.46) | TSHRSMN1; SMN2ALDH1A1KMT2ACA14 | |
| SCHEMBL6669595 | 0.89 | SMN1; SMN2 (0.46) | TSHRSMN1; SMN2ALDH1A1KMT2ACA14 | |
| SCHEMBL31276635 | 0.89 | SMN1; SMN2 (0.46) | TSHRSMN1; SMN2ALDH1A1KMT2ACA14 | |
| SCHEMBL11980977 | 0.89 | SMN1; SMN2 (0.46) | TSHRSMN1; SMN2ALDH1A1KMT2ACA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250009621-A1 | ANHYDROUS HAIR TREATMENT COMPOSITION COMPRISING ALPHA HYDROXY ACID ESTER | L'OREAL (FR) | 2025-01-09 | — | — | US | disclosed |
| WO-2025006991-A1 | ANHYDROUS HAIR TREATMENT COMPOSITION COMPRISING ALPHA HYDROXY ACID ESTER | L'OREAL (FR) | 2025-01-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250009621-A1 | ANHYDROUS HAIR TREATMENT COMPOSITION COMPRISING ALPHA HYDROXY ACID ESTER | EBP, ADH1A, ADH1C | PDE4A 1325/4885TSHR 3405/4885CYP2C9 2101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.